Date: August 10, 2026
Industry View: Cautiously Bullish (pipeline advancing but clinical validation has yet to cross the valley of death)
Time Horizon: 12-24 months
Research Archetype: R&D-driven — pipeline and catalysts as headline, policy/regulatory upgrades as core variable
AI Drug Discovery refers to the drug R&D segment driven by artificial intelligence/machine learning technologies, covering the full chain from target discovery, molecular design/generation, preclinical optimization to patient stratification in clinical trials.
Industry Chain Map: AI technology platforms (algorithms + compute + data) → Target discovery and validation → Molecular design and optimization → Preclinical research → Clinical trials (Phase I-III) → Regulatory approval → Commercialization. AI's value-add diminishes along the chain: AI advantages are strongest in target discovery and molecular design (virtual screening scope expanded from ~1 million compounds traditionally to 20 billion), while in clinical stages AI's advantage reverts to levels comparable with traditional drug development.
Four Categories of Players:
Key Boundary Definition: This report focuses on "AI as the core driving engine for drug discovery" — i.e., assets and companies where AI plays an irreplaceable role in designing/screening/optimizing molecules. Pharma projects where AI is merely "assistive" (e.g., supporting data analysis in existing pipelines, non-decisive contribution) fall outside the core research scope, though they are touched upon in the partnership network section.
The global pharmaceutical industry faces three unsustainable R&D economic metrics: ①Average cost of $2.6 billion per drug (Tufts CSDD basis; RAND's 2024 JAMA paper adjusts median to ~$708 million and mean to ~$1.31 billion, reflecting differences in sample and methodology); ②Timeline of 10-15 years from target to approval; ③Overall Phase I-to-approval success rate of ~10% (MIT Wong/Siah/Lo study). AI's core value proposition is to compress these metrics — even a 20-30% compression would unlock tens of billions of dollars in economic value.
The global AI drug discovery market (software + services + collaboration revenue basis) was approximately $6.9 billion in 2025, projected to reach approximately $11.9 billion by 2030 (CAGR ~11.4%), broadly consistent with Precedence Research ($11.3 billion, CAGR 10.1%) and Statista ($11.9 billion). Morgan Stanley, using a broader value framework, estimates AI could deliver 50 new therapies and over $50 billion in incremental innovative drug value globally within 10 years.
China's market is growing faster: ~$104 million in 2023 → ~$809 million by 2030 (CAGR ~34%, Grand View Research).
⚠️ Basis Warning: AI drug discovery market size estimates vary 3-4x across sources (Astute Analytica $8.1 billion vs Research and Markets $29.9 billion), depending on whether pipeline potential value, internal R&D spending, etc. are included. This report's headline uses the narrow "software + services + collaboration revenue" basis, which is most consistent with the bottom-up bridge.
Bridge Logic: Global pharma R&D spending of ~$250 billion (2025, including Big Pharma + Biotech; IQVIA basis of 15 large pharmas ~$163 billion, higher on a global all-inclusive basis) → ~$320 billion by 2030 (+5% annually). AI's share of R&D spending rises from ~2.8% in 2025 to ~3.7% by 2030 — the combination generates a net increment of ~$4.9 billion.
| Driver | Incremental Contribution (US$B) | Logic |
|---|---|---|
| R&D base growth ($250B→$320B) | 2.59 | $70B increment × 3.7% AI penetration |
| AI penetration increase (2.8%→3.7%) | 2.33 | $250B base × +0.93pp |
| Total net increase | 4.92 | 6.93 + 4.92 ≈ 11.85 ≈ 11.9 |
Sources: IQVIA 'Global Trends in R&D 2025', Precedence Research, Morgan Stanley 'AI Drug Discovery'
Opening of undruggable targets: ~85% of the human proteome remains undruggable (C&EN/CancerTools basis), with only ~700 proteins serving as targets for FDA-approved drugs. AI + PROTAC/molecular glue and other novel mechanisms are opening this space — Insilico's TNIK (IPF) and Recursion's RBM39 (molecular glue) are both first-in-class attempts at entirely novel targets.
Big Pharma shifting from pilots to scaled deployment: ~81% of pharma companies have deployed AI (Axis Intelligence), but deep integration across the full R&D workflow remains rare. BMS deploying Schrödinger's Bunsen, Eli Lilly-NVIDIA's $1 billion AI lab collaboration, and Isomorphic Labs' $2.1 billion Series B completed in May 2026 (the second-largest financing in biotech history) mark the shift from "trying it out" to "strategic commitment."
Generative AI technology leap: AlphaFold series, generative chemistry engines (Chemistry42, IsoDDE), and agentic AI co-scientists have expanded virtual screening scope 20,000-fold (1 million → 20 billion compounds), improving candidate identification efficiency by ~18-20x (Exscientia requires only 150-400 molecules to enter the clinic vs. 5,000 traditionally).
AI drug discovery is currently at the critical juncture of transitioning from early adopters to early majority. Penetration is ~5% (by pipeline/R&D spend share), and the key signal is the first approval of an AI-designed drug — analysts expect this in 2027-2028 (rather than the previously optimistic 2026), with ~25-30% probability (see I7 Controversy Analysis for details). Once the first approval lands, it will trigger the mainstream adoption acceleration phase.
Leading Indicators:
As of August 2026, the AI drug discovery sector has 0 AI-native pipeline assets approved. The pipeline exhibits a classic "pyramid" structure: preclinical + Phase I dominate, Phase II has only a handful, and Phase III has just 2. 4 assets have been terminated (Recursion's REC-2282/REC-3964, Schrödinger's SGR-2921, Exscientia's EXS21546), highlighting the systemic risk that "platform throughput ≠ clinical success rate."
| Asset | Company | Target | Indication | Phase | Key Readout Timing |
|---|---|---|---|---|---|
| rentosertib (ISM001-055) | Insilico Medicine | TNIK | IPF | Phase III | Ph3 initiated 2026-07, primary endpoint 2029-10; China NDA window 2027-2028 |
| RLY-2608 (zovegalisib) | Relay Therapeutics | PI3Kα (mutant-selective) | HR+/HER2- breast cancer | Phase III | ReDiscover-2 primary endpoint 2028-04 |
| garutadustat (ISM5411) | Insilico Medicine | PHD1/2 (gut-restricted) | Ulcerative colitis | Phase II | BETHESDA Ph2a 2027-08 |
| REC-1245 | Recursion | RBM39 (molecular glue) | Solid tumors/lymphoma | Phase I/II | Ph1 dose escalation data 2026H1 window |
| GTAEXS617 | Recursion/Exscientia | CDK7 | Solid tumors | Phase I/II | Primary endpoint 2028-01 |
| REC-4881 | Recursion | MEK1/2 | FAP | Phase I/II | Primary endpoint 2027-06 |
| SGR-3515 | Schrödinger | WEE1 | Solid tumors | Phase I | 2026-10 (near-term) |
| ISM8207 | Insilico Medicine | QPCTL | Solid tumors/B-cell lymphoma | Phase I | 2026-11 (near-term) |
| ISM8969 | Insilico Medicine | NLRP3 (brain-penetrant) | Parkinson's/inflammation | Phase I | 2027-01 (near-term) |
| SGR-1505 | Schrödinger | MALT1 | B-cell lymphoma | Phase I | Primary endpoint 2027-11 |
| EXS73565 | Recursion/Exscientia | MALT1 | B-cell malignancies | Phase I | Primary endpoint 2028-06 |
| RLY-8161 | Relay Therapeutics | NRAS (G12D etc.) | Solid tumors/melanoma | Phase I | Primary endpoint 2027-12 |
| ABS-201 | Absci | de novo antibody | Androgenetic alopecia | Phase I/II | Primary endpoint 2028-07 |
Sources: ClinicalTrials.gov, company disclosures (NCT numbers in Appendix)
Modality Distribution: Dominated by oral small molecules (~90% of clinical pipeline); protein degradation via molecular glue (REC-1245 RBM39, not PROTAC); biologics are a minority (Absci ABS-201 is a de novo designed antibody). No PROTAC/gene editing/cell therapy has entered AI-native clinical pipelines. This reflects AI drug discovery's current strength in "design and optimization of druggable small molecules against novel targets," rather than complex biologic modalities.
| Target | Number of Drugs in Development | Crowding | AI Positioning Logic |
|---|---|---|---|
| TNIK | 0 (Open Targets) | Empty | Insilico's rentosertib is the only one globally — absolute first-in-class |
| QPCTL | 0 (Open Targets) | Empty | Insilico's ISM8207 is the only one in development, avoiding CD47's RBC toxicity |
| RBM39 | 0 (Open Targets) | Empty | Recursion's REC-1245 molecular glue degradation — novel target discovered via AI phenotyping |
| MALT1 | 2 (clinical) | Low | Schrödinger SGR-1505 + Recursion EXS73565 duopoly |
| WEE1 | 2 | Low | Schrödinger SGR-3515, but azenosertib has already advanced to Ph3 as leader |
| CDK7 | 9 | Moderately crowded | Recursion's GTAEXS617 positioned on best-in-class selectivity |
| PIK3CA | 32 | High | Relay's RLY-2608 differentiates via mutant selectivity + allosteric mechanism |
| EGLN1 (PHD) | 5 (all approved) | High | Insilico's garutadustat differentiates via gut restriction + IBD focus |
Sources: Open Targets, ClinicalTrials.gov
The next 12-18 months represent a dense window of near-term clinical readouts for AI drug discovery. Key catalyst calendar below:
| Time Window | Asset | Event | Importance | Impact Direction |
|---|---|---|---|---|
| 2026H1 window | REC-1245 (RBM39) | Ph1 dose escalation data | ⭐⭐⭐ | First end-to-end AI platform asset readout for the merged entity |
| 2026-10 | SGR-3515 (WEE1) | Ph1 primary endpoint | ⭐⭐⭐ | Schrödinger computational platform clinical validation |
| 2026-11 | ISM8207 (QPCTL) | Ph1 primary endpoint | ⭐⭐⭐ | First readout of first-in-class CD47-SIRPα novel mechanism |
| 2027-01 | ISM8969 (NLRP3) | Ph1 readout | ⭐⭐ | Adds CNS large-indication optionality |
| 2027-06 | REC-4881 (MEK) | Ph1/2 readout | ⭐⭐ | MEK allosteric differentiation validation |
| 2027-08 | garutadustat (PHD) | BETHESDA Ph2a | ⭐⭐⭐ | First IBD efficacy validation of gut-restricted PHD inhibitor |
| 2027-2028 | rentosertib (TNIK) | China NDA filing window | ⭐⭐⭐⭐⭐ | Global first AI drug approval milestone |
| 2028-04 | RLY-2608 (PI3Kα) | ReDiscover-2 Ph3 primary endpoint | ⭐⭐⭐⭐⭐ | Heaviest catalyst in the entire sector |
warn:trueflags high-risk, high-reward events — their outcomes will determine sector-wide valuation re-rating or collapse.
As of August 2026, no drug discovered and designed purely by AI has been approved globally. Among the 46 new drugs approved by the FDA in 2025 (e.g., Jascayd/nerandomilast for IPF, Lipfendra/enlicitide oral PCSK9), AI contributed as an assistive tool rather than the core driver, and these are not counted as AI-native pipelines.
As of August 2026, the sector has zero approved assets, with no relevant patent cliff records in the Orange Book / Purple Book. Exclusivity is a long-dated issue — investors are currently focused on clinical readouts rather than patent expiry risk. Key concern: USPTO's "non-obviousness" standard for AI-discovered molecules may be raised given AI's large-scale molecular output — a medium-to-long-term concern for patent value (see I6.2).
There are 350+ AI drug discovery companies globally (industry broad basis ~700), with no winner-take-all dynamic, but deal value is concentrating toward a few leaders with "proprietary data + wet-lab closed loop."
Note: XtalPi FY2025 revenue of HK$803 million, converted at 7.8 HKD/USD ≈ $103 million. Sources: Company FY2025 annual reports.
| Company | Ticker | Type | FY2025 Revenue | Net Income/Loss | Core Moat | One-Liner |
|---|---|---|---|---|---|---|
| Recursion | RXRX | AI-native biotech | $75M | Net loss $645M | Largest proprietary phenomics dataset + wet-lab closed loop | Industry consolidator, aggressive cash burn |
| Schrödinger | SDGR | Software + CRO | $256M | Adjusted EBITDA -$115M | Physics-based FEP+ algorithms + recurring software revenue | Closest to a "good business" in the sector |
| Relay Tx | RLAY | AI-native biotech | $15M | Net loss $276M | Molecular dynamics + protein conformational design | High-beta asset where a single program determines fate |
| XtalPi | 2228.HK | CRO + AI | HK$803M | Net profit attributable to parent +HK$124M | AI + automated lab wet-lab closed loop | Reported turnaround, but cash flow still negative |
| Insilico Medicine | Unlisted (HK IPO planned) | AI-native biotech | N/A | N/A (in fundraising) | Generative AI platform + world's most advanced AI pipeline | Global benchmark for the "self-owned pipeline" model |
| AbCellera | ABCL | AI antibody platform | $75M | Net loss $146M | Single-cell + AI antibody discovery proprietary data | Deep losses despite rapid revenue growth |
| Absci | ABSI | AI SaaS/platform | $3M | Net loss $115M | Generative AI de novo antibody design | High valuation, minimal revenue, heavy cash burn |
Source: Company FY2025 annual/quarterly reports; XtalPi PE(TTM) 255/PB 3.37 (14th percentile historical), RXRX price $3.22 (YTD -23%), SDGR price $18.16 (YTD +1%), RLAY price $19.77 (YTD +142%, up over 10x from 2024 low of $1.77).
The current profit pool does not reside within AI pharma companies. Nearly all AI-native biotechs are deeply loss-making, sustained by fundraising and upfront payments. Profits remain in two segments:
Profit migration over the next 2-3 years: shifting from "software licensing + upfront payments" toward "milestones + royalties + value of self-owned pipelines." The driver is AI drugs entering the Phase III readout window — Goldman Sachs forecasts AI-assisted innovative drugs will account for over 50% of BD transactions by 2027, exceeding $80B in value.
Key judgment: Profits in the pure "algorithm/tool" segment will be squeezed and transferred to big pharma's internal AI (approximately 30-40% planned in-house or hybrid strategies) and tech giants like NVIDIA. Companies with genuine "proprietary data + wet-lab closed loop" (Recursion, XtalPi, Insilico Medicine) will capture more value.
| Date | Partners | Nominal Total Value | Upfront Payment | Description |
|---|---|---|---|---|
| 2025-08 | XtalPi × DoveTree | ~$5.9B | $51M | Molecular glue collaboration, largest single AI drug discovery deal in the industry |
| 2025-06 | AstraZeneca × CSPC Group | $5.33B | N/A | AI platform strategic partnership |
| 2024-11 | Novartis × Schrödinger | Potential $2.3B | $150M | Multi-target collaboration |
| 2025-04 | Sanofi × Helixon | $1.845B | N/A | Bispecific antibodies HXN-1002/1003 |
| 2026-01 | Eli Lilly × NVIDIA | Over $1B | — | Co-building AI supercomputing lab |
| 2022-01 | Sanofi × Exscientia | Up to $5.2B | ~$100M | AI small molecule discovery (transferred to Recursion post-merger) |
⚠️ Biobucks Warning: The vast majority of the "nominal total values" above are contingent milestones (biobucks); the industry-wide upfront/announced value ratio is approximately 1:50. For instance, the Sanofi-Exscientia deal announced at $5.2B had an actual upfront of only ~$100M (~1.9%). These deals reflect big pharma's strategic "option-keeping" positioning rather than a full-scale bet on AI.
Overall return quality: Poor. Most AI pharma companies exhibit a prosperity illusion of rising revenue without rising profits — revenue and BD deal values grow strongly, while net losses persist and cash burn remains aggressive.
Value trap risk: High. High valuations (RXRX price-to-sales ~25x, RLAY ~267x) + deep losses + unimproved clinical success rates = a classic "prosperity optimism ≠ worth buying" sector. See I8 decision matrix.
A-share biopharma sector (Shenwan Biological Products 801152.SI, used as proxy since no standalone AI pharma index exists): PE ~44.73 (44th percentile historical), PB ~2.24 (5th percentile historical, extremely low range over the past decade) — the sector overall is not expensive, but listed AI pharma companies are concentrated in the US/HK markets and all trade at high valuations with losses. XtalPi PE(TTM) 255, PB 3.37 (14th percentile historical); RXRX price-to-sales ~25x, SDGR ~5x, RLAY ~267x — all loss-making, with valuation anchored on pipeline optionality rather than current earnings.
The policy environment is an overall positive structural tailwind for AI pharma, but US-China geopolitical risks pose a tail threat.
| Region | Policy/Guidance | Direction | Key Points |
|---|---|---|---|
| US FDA | 2025-01 Draft "Considerations for the Use of AI…" (expected finalization 2026Q2) | Positive | Seven-step credibility framework; explicitly excludes early drug discovery (target/lead optimization) from mandatory validation scope; formally recognizes AI tools under DDT/BQP pathways |
| US FDA + EMA | 2026-01-14 Joint release of 10 GAiP principles | Positive | Global harmonization reduces compliance uncertainty |
| China NMPA | 30-working-day fast track from 2025-10 (priority innovation/global simultaneous/pediatric rare diseases) | Positive | AI-discovered drugs eligible for priority review as innovative drugs; 2026-04 issued "AI + Drug Regulation" implementation opinions |
| China CDE | 2026-07 ICH M15 (MIDD) consultation | Positive | Paves the way for computational/model-based evidence in regulatory review |
| EU | EU AI Act (effective 2024-08), drug R&D AI generally falls outside high-risk due to "scientific research exemption" | Positive | Explicitly exempts early-stage R&D AI from high-risk regulation |
Source: FDA Guidance FDA-2024-D-4689; NMPA Announcement No. 86; NMPA Comprehensive Document No. 6 (2026)
Core risk: The USPTO has not yet ruled on whether "AI's mass generation of molecules renders the entire class obvious." Generative AI routinizes chemical space exploration, potentially raising the non-obviousness bar and expanding the "obvious to try" defense — this would directly compress patent breadth and exclusivity value for AI-discovered molecules.
Inventorship: The US (USPTO/Federal Circuit), Europe (EPO), and the UK all require natural persons as inventors (DABUS cases), treating AI as a tool. Germany (BGH 2024) and Switzerland (2025 first instance) are relatively permissive. China/Canada DABUS applications remain pending or under appeal. Divergent national positions increase cross-border patent strategy complexity, but overall this does not constitute a systemic negative.
Source: USPTO AI-assisted invention guidance; Science (Rai/Freilich 2025); Artificial Inventor Project
| Policy | Status | Direction | Material Impact |
|---|---|---|---|
| BIOSECURE Act (FY2026 NDAA §851) | Enacted (2025-12-18) | Negative | Restricts federal procurement/funding from using "biotechnology companies of concern" for gene sequencers, biological data storage/transmission, and disease detection services. Targets China's sequencing/gene services chain, posing supply-chain disruption risk to AI pharma's data + sequencing segments |
| COINS Outbound Investment Rules | Enacted (2025-12), biotech not yet included | Pending negative | Currently covers only AI/semiconductors/quantum, but Section 809 authorizes Treasury to add sectors. Congress has publicly proposed including biotech — if enacted, would restrict US investment in and licensing deals with Chinese AI pharma. Treasury must publish final implementing regulations by 2027-03-13 |
| China HGR Regulation Revision | Consultation (2026-05-08) | Positive | HGR information narrowed to nucleic acid sequences; foreign entity threshold changed to 50% shareholding; filing confirmation on the same day — significantly lowers cross-border data compliance barriers for foreign AI pharma |
Source: Baker McKenzie sanctions blog; Morgan Lewis LawFlash (2026-05-15); NHC consultation draft
ESG Impact: Limited. The carbon footprint of AI training compute is a marginal concern; ESG capital flows generally favor innovative healthcare assets. No industry-wide environmental production restrictions or carbon tariffs.
| Bull | Bear | |
|---|---|---|
| Core Argument | Top pharma AI partnerships are intensifying (Sanofi-Exscientia $5.2B, Isomorphic $3B, Lilly-NVIDIA over $1B); AI-designed molecule pipeline grew from 15 to 200+; market grew from $6.9B to $11.9B | Nominal deal values are mostly biobucks (industry upfront/announced ratio ~1:50); pipeline growth counts molecule numbers, not success rates — Phase 2 success rate ~40%, unchanged from traditional methods |
| Tracking Indicators | Top pharma AI partnership renewals/new signings; AI drug Phase 2/3 success rates vs. industry average | Bayer-Exscientia partnership terminated; Exscientia absorbed into Recursion (both companies' market caps shrank significantly post-IPO); multiple companies cut 20%+ of workforce in 2025 |
Red Team Verdict: The bear attack partially holds. The gap between biobucks and cash is real — exemplified by the Exscientia $5.2B deal with only $100M upfront. The "200+" pipeline count prosperity masks the structural weakness of unimproved success rates. The inflection point narrative should be downgraded to a "consolidation and shakeout phase" — the industry is eliminating losers rather than entering mainstream scaling.
| Bull | Bear | |
|---|---|---|
| Core Argument | rentosertib Phase 2a data impressive (+98.4mL FVC); China NDA window 2027-2028 | rentosertib Phase III only starts July 2026 (320 patients, 47 sites in China only, 52-week endpoint); approval before 2028 nearly impossible. IPF is notorious for Phase 3 failures; historically many Phase 2-positive assets failed in Phase 3 |
| Tracking Indicators | rentosertib China NDA submission announcement; RLY-2608 ReDiscover-2 interim analysis | Per industry funnel (Ph1 85% × Ph2 40% × Ph3 50% × filing 85%), cumulative probability of any AI drug from Phase I to approval is only ~14.5%, far below the previously optimistic ~60% |
Red Team Verdict: The bear attack holds. The ~60% probability is a serious overestimate — should be revised down to the industry funnel ~14.5% (single asset). The reasonable window for first AI drug approval is 2028-2029, not 2026-2027. However, multi-asset pipelines provide diversification — even if rentosertib fails, RLY-2608's Phase 3 constitutes an independent catalyst.
| Bull | Bear | |
|---|---|---|
| Core Argument | Schrödinger proves a sustainable software licensing business model; 12% royalty on a $2B peak-sales drug = $240M/year high-margin annuity | The vast majority of AI-native biotechs are deeply loss-making, burning hundreds of millions annually; even with pipeline success, the bulk of profits is captured by big pharma |
| Tracking Indicators | Schrödinger software revenue growth; XtalPi operating cash flow breakeven timing; royalty terms of first approved AI drug | Recursion FY2025 net loss $645M, annual cash burn ~$400M; in the $11.9B industry market, independent AI companies' addressable share may be under $3B |
Red Team Verdict: The bear attack partially holds but over-extrapolates. Schrödinger (software platform) must be valued separately from Recursion (clinical biotech) — the former has a sustainable recurring revenue model, the latter remains a high-risk option. A 12% royalty can indeed generate an order-of-magnitude shift in a success scenario, but only if the drug succeeds first — and that is a low-probability event.
| Scenario | Probability | Narrative | Investment Implications |
|---|---|---|---|
| 🐻 Bear | 25% | Either rentosertib/RLY-2608 Phase 3 fails or is delayed >12 months; multiple Phase 1/2 readouts negative; ≥2 big pharma AI partnerships terminated. First AI drug approval pushed beyond 2030 | Sector-wide valuation collapse; only Schrödinger-type software companies offer defensive value; pure pipeline companies face financing winter and heavily discounted dilutive raises |
| 📊 Base | 50% | Pipeline readouts half positive, half negative (consistent with industry funnel); first AI drug approval around 2029; big pharma partnerships maintained but not accelerating. AI penetration rises slowly at ~11% CAGR | Divergence intensifies: companies with Phase 3 assets + software revenue outperform; pure early-stage pipeline companies continue burning cash under pressure. Sector valuations recover modestly |
| 🐂 Bull | 25% | rentosertib approved in China (2028), RLY-2608 Phase 3 data positive (2028); multiple Phase 2 readouts positive. AI penetration accelerates to 15%+. Big pharma partnerships upgrade to M&A | Sector-wide re-rating: AI pharma shifts from "option" to "delivery," leader valuations double, IPO window opens |
| Date | Event | Impact | Corresponding Debate |
|---|---|---|---|
| 2026-10 | SGR-3515 Phase 1 readout | Near-term directional | D2 |
| 2026-11 | ISM8207 Phase 1 readout | Near-term directional | D2 |
| 2027-01 | ISM8969 Phase 1 readout | Near-term directional | D2 |
| 2027-03 | COINS outbound investment final regulations (whether biotech is included) | Extreme tail risk | D1 |
| 2027-08 | garutadustat Phase 2a readout | Medium-term directional | D2 |
| 2027-2028 | rentosertib China NDA filing | Sector milestone | D1, D2, D3 |
| 2028-04 | RLY-2608 ReDiscover-2 Phase 3 primary endpoint | Most significant sector-wide catalyst | D1, D2, D3 |
Quadrant Interpretation:
Top-right (Core Allocation Zone): Big pharma internal AI — not independently listed, but indicates that AI pharma's value ultimately anchors with the holders of drug commercialization. Schrödinger sits near the top-right — software recurring revenue provides the industry's most stable return base.
Bottom-right (Value Trap Zone): Recursion (RXRX) and Relay (RLAY) have solid prosperity direction (both have Phase 3/key pipelines), but extremely poor business quality (deep losses + hundreds of millions in annual cash burn). Prosperity optimism ≠ worth buying: if pipelines fail, current high price-to-sales ratios (RXRX ~25x, RLAY ~267x) have zero fundamental support. Insilico Medicine has the highest prosperity direction but similarly low business quality — a high-risk, high-reward bet that is "closest to delivery, but zero if it fails."
Top-left (Distressed Turnaround Candidates): Pure algorithm/SaaS tool companies — could stage a comeback if they find unique data moats or vertical integration paths. Currently squeezed by big pharma internal AI and tech giants.
Bottom-left (Avoid Zone): Absci (ABSI) — minimal revenue ($3M), heavy cash burn (annual loss of $115M), platform value far from clinical validation — an extreme example of the "prosperity illusion."
Beneficiary Targets:
Insilico Medicine (Planned HK IPO): The world's most advanced AI pipeline (rentosertib Phase III). A successful China NDA would mark the "first AI-discovered drug approval" milestone. Risks: High IPF Ph3 failure rate, company not yet profitable, valuation TBD.
Schrödinger (SDGR): The segment closest to a "good business" in the industry—recurring software revenue (~$200M/year) plus major collaborations with Novartis and others. Most defensive, relatively resilient in pipeline-failure scenarios.
XtalPi (2228.HK): Monetizing via an AI+CRO model, an "AI version of CXO"—the ~$5.9B DoveTree deal validates platform value. Financials have turned profitable but operating cash flow remains negative; watch for the inflection point to positive cash flow.
Avoid Targets:
Absci (ABSI): Minimal revenue ($3M), deep losses (annual loss of $115M), valuation entirely dependent on the "AI de novo antibody design" narrative—no near-term clinical catalysts for validation. A classic value trap.
Pure algorithm/SaaS tool startups (pre-IPO): Weakest moats, most susceptible to replacement by in-house AI at large pharma and tech giants like NVIDIA. Unless they possess proprietary data moats.
| Scenario | Most Benefited Targets | Most Hurt Targets | Rationale |
|---|---|---|---|
| 🐻 Bear | Schrödinger (SDGR) | Relay (RLAY), Recursion (RXRX) | Recurring software revenue is a safe harbor; pure-pipeline companies face valuation collapse |
| 📊 Base | Insilico Medicine + Schrödinger | Absci (ABSI) | Companies with Ph3/software lead; pure platforms without catalysts remain squeezed |
| 🐂 Bull | Insilico Medicine, Relay (RLAY), Recursion (RXRX) | — | Broad-based gains; pipeline companies offer the highest upside |
This report is based on public information and industry analysis and does not constitute investment advice. AI drug discovery is a high-risk early-stage sector with pipeline failure rates exceeding traditional pharma averages; investors should fully recognize the coexistence of option value and zero-out risk.
Key Sources: Precedence Research, Morgan Stanley『AI Drug Discovery』, BCG『Adopting AI in Drug Discovery』, IQVIA『Global Trends in R&D 2025』, FDA Guidance FDA-2024-D-4689, ClinicalTrials.gov, Company FY2025 Annual Reports/Quarterly Reports, Open Targets, Drug Target Review 2026 Predictions, Jayatunga et al. Drug Discovery Today 29(6):104009 (2024)